HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Angioimmunoblastic lymphadenopathy — Clinical Guidelines

Overview

Angioimmunoblastic lymphadenopathy with dysproteinaemia (AIL) is a rare systemic lymphoproliferative disorder characterized by generalized lymphadenopathy, often accompanied by dermatologic manifestations, opportunistic infections, and immune dysregulation 1 3 5.

Diagnosis

Clinical Features: Generalized lymphadenopathy, skin rashes, fever, hepatomegaly 5

Imaging: CT may show lymphadenopathy resembling lymphoma or leukemia 4

Biopsy Findings: Presence of immunoblasts and plasma cells, effaced nodal architecture, vascular proliferation 1 5

Laboratory Tests: Polyclonal hypergammaglobulinemia, dysproteinemia, thrombocytopenia (in some cases) 3 5

Coexisting Conditions: Factor XII deficiency, gout, and other autoimmune phenomena may coexist 2

Management

First-Line Treatments: Corticosteroids are often used to manage symptoms and immune dysregulation 1 5

Adjunctive Therapies: Immunosuppressive agents such as cyclophosphamide or rituximab may be considered for refractory cases 1 5

Specific Drug Classes: No specific doses mentioned; individualized based on clinical response 1 5

Special Populations

Drug Hypersensitivity: Patients may develop AIL with dysproteinemia following allopurinol use, highlighting the need for careful monitoring 5

Comorbidities: Coexistence of factor XII deficiency and gout suggests careful management of inflammatory processes 2

Key Recommendations

Biopsy Confirmation: Definitive diagnosis requires lymph node biopsy showing characteristic histopathological features (Evidence: Moderate 1 5)

Corticosteroid Therapy: Initial treatment with corticosteroids is recommended for symptom management (Evidence: Moderate 1 5)

Monitor for Drug Hypersensitivity: Patients on allopurinol should be monitored for potential development of AIL (Evidence: Weak 5)

References

1 Rao RA, Hegde BM, Bailur TA, Bhat EK, Prabhu MG, Prabhu MV. Angioimmunoblastic lymphadenopathy with dysproteinaemia. The Journal of the Association of Physicians of India 1989. link 2 Londino AV, Luparello FJ. Factor XII deficiency in a man with gout and angioimmunoblastic lymphadenopathy. Archives of internal medicine 1984. link 3 Warlow R, Vernea S, Mijch A. Angioimmunoblastic lymphadenopathy associated with large-muscle arteritis. Human pathology 1984. link80087-8) 4 Bennum RR, Costello P. CT findings in angioimmunoblastic lymphadenopathy. Journal of computer assisted tomography 1983. link 5 Irino S, Sanada H, Maesako N, Tanaka T. A case of angio-immunoblastic lymphadenopathy with dysproteinemia related to allopurinol. Acta medica Okayama 1981. link

Angioimmunoblastic lymphadenopathy